Search Results
May 14, 2026, 16:05 ET Academy Sports + Outdoors Announces Closing of Senior Secured Notes
KATY, Texas, May 14, 2026 /PRNewswire/ -- Academy Sports and Outdoors, Inc. ("Academy") (Nasdaq: ASO) today announced that its wholly-owned subsidiary, Academy, Ltd. (the "Issuer"), closed its private placement under Rule 144A and Regulation S under
More news about: Academy Sports + Outdoors
May 07, 2026, 08:04 ET Silva Capital Solutions Advises Propel HR in Acquisition by OneDigital
as individual payroll and HR solutions. Based out of Greenville, SC, with operations in 49 states, Propel HR's Administrative Service Organization (ASO) and Professional Employer Organization (PEO) support their clients' demands for HRMS and Payroll solutions supporting small and mid-sized companies.
More news about: Silva Capital Solutions, Inc.
May 07, 2026, 07:00 ET Evolent Announces First Quarter 2026 Results
FeePerformance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology
More news about: Evolent Health, Inc.
May 04, 2026, 16:55 ET Academy Sports + Outdoors Announces Pricing of Senior Secured Notes
KATY, Texas, May 4, 2026 /PRNewswire/ -- Academy Sports and Outdoors, Inc. ("Academy") (Nasdaq: ASO) today announced that its wholly-owned subsidiary, Academy, Ltd. (the "Issuer"), priced a private offering that is exempt from the registration requirements
More news about: Academy Sports + Outdoors
May 04, 2026, 08:20 ET Academy Sports + Outdoors Announces Offering of Senior Secured Notes
KATY, Texas, May 4, 2026 /PRNewswire/ -- Academy Sports and Outdoors, Inc. ("Academy") (Nasdaq: ASO) today announced that its wholly-owned subsidiary, Academy, Ltd. (the "Issuer"), intends to offer $500 million aggregate principal amount of senior secured
More news about: Academy Sports + Outdoors
Apr 30, 2026, 15:34 ET Vensure Employer Solutions CEO Alex Campos Named Entrepreneur of the Year as Company Earns 14 Gold, Silver, and Bronze Stevie® Awards in 2026 American Business Awards®
information. About PrismHR PrismHR, a Vensure Employer Solutions company, is a premier technology platform purpose-built for the PEO and ASO service bureau market. PrismHR provides service bureaus with the infrastructure to efficiently manage payroll, benefits, HR, and compliance on behalf
More news about: Vensure Employer Solutions
Apr 28, 2026, 12:21 ET CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTD
AS-241 is an antisense oligonucleotide (ASO) designed to address a core molecular consequence of ALS and FTD driven by dysfunction of the protein TDP–43. Pathological loss of nuclear TDP–43 leads
More news about: AcuraStem - Patient-Based Therapeutics
Apr 20, 2026, 16:35 ET Vensure Employer Solutions Launches HR Compliance, an AI-powered platform delivering real-time compliance guidance
regulations with greater speed and confidence.PrismHR, a Vensure Employer Solutions company and a leading technology platform serving the PEO and ASO service bureau market, will offer
More news about: Vensure Employer Solutions
Apr 13, 2026, 08:01 ET Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update
in schizophrenia patients is on track to begin mid-2026, with initial data expected by year-end. LTX-002, an intrathecal antisense oligonucleotide (ASO) targeting SPTLC1 for genetic and sporadic ALS, has completed key preclinical studies with a Phase 1/2 trial on track to initiate in 1H 2026. Additional
More news about: Leal Therapeutics
Apr 10, 2026, 08:00 ET Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
expertise, Vivatides has built a differentiated extrahepatic delivery platform with capabilities spanning both siRNA and antisense oligonucleotides (ASO). The company has achieved key advances in ligand conjugation, delivery efficiency, tissue targeting specificity, and safety, with encouraging in vivo
More news about: Vivatides Therapeutics
Apr 07, 2026, 16:59 ET AppTweak Launches First Platform to Measure and Optimize App Discovery in AI Search
search. Trusted by thousands of apps worldwide, AppTweak provides powerful data, insights, automation, and AI to strengthen App Store Optimization (ASO), Apple Ads performance, and AI app discovery.Media Contact:[email protected]
More news about: AppTweak
Apr 07, 2026, 09:00 ET Academy Sports + Outdoors Hosts 2026 Analyst Day Event
Academy Sports + Outdoors ("Academy" or the "Company") (Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, is hosting its Analyst Day event today, April 7, 2026, beginning at 9:00 a.m. Eastern
More news about: Academy Sports + Outdoors
Apr 07, 2026, 08:05 ET Academy Sports + Outdoors Announces Preliminary First Quarter Fiscal 2026 Sales Update Ahead of its Analyst Day
Academy Sports + Outdoors ("Academy" or the "Company") (Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today provided an update on its first quarter fiscal 2026 sales and comparable sales
More news about: Academy Sports + Outdoors
Apr 02, 2026, 08:05 ET Academy Sports + Outdoors Announces Participation in Upcoming Investor Conference
Nasdaq: ASO), a leading full-line sporting goods and outdoor recreation retailer, today announced its participation in the upcoming J.P. Morgan Retail Roundup Conference to
More news about: Academy Sports + Outdoors
Mar 31, 2026, 16:30 ET Academy Sports + Outdoors Announces 2026 Analyst Day Event
Academy Sports + Outdoors ("Academy" or the "Company") (NASDAQ: ASO), a leading full-line sporting goods and outdoor recreation retailer, plans to host an Analyst Day event on April 7, 2026.
More news about: Academy Sports + Outdoors
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
platform technologies, including HCAb-based blood-brain barrier (BBB) shuttle platforms for brain-penetrant antibody delivery and BBB shuttle-conjugated ASO/siRNA modalities, designed to overcome the key barriers in CNS drug development.Powering Next-Generation Therapeutics Through Platform Innovation
More news about: Harbour BioMed
Mar 28, 2026, 15:01 ET Институт Critical Path Institute запускает программу One to Millions, чтобы изменить будущее персонализированной медицины в глобальном масштабе
для предоставления персонализированных ASO-препаратов пациентам с нано-редкими заболеваниями. На сегодняшний день мы открыли и разработали более 25 ASO-препаратов, которые позволили лечить более 45 пациентов с нано-редкими заболеваниями. Многие из этих новых ASO-препаратов можно использовать для лечения
More news about: Critical Path Institute
Mar 28, 2026, 14:39 ET Das Critical Path Institute startet die Initiative „One to Millions", um die Zukunft der personalisierten Medizin weltweit neu zu gestalten
extrem seltenen Erkrankungen mit maßgeschneiderten ASO-Medikamenten zu versorgen. Wir haben mehr als 25 ASOs entdeckt und entwickelt, die es bisher ermöglicht haben, mehr als 45 Patienten mit extrem seltenen Erkrankungen zu behandeln. Viele dieser neuen ASO-Medikamente können zur Behandlung weiterer Patienten
More news about: Critical Path Institute
Mar 27, 2026, 13:25 ET Critical Path Institute spouští iniciativu „Jedna k milionům" s cílem přetvořit budoucnost personalizované medicíny v globálním měřítku
s extrémně vzácnými onemocněními individualizované léky na bázi ASO. Objevili a vyvinuli jsme více než 25 ASO, díky nimž bylo dosud možné léčit více než 45 pacientů s extrémně vzácnými onemocněními. Mnohé z těchto nových léků na bázi ASO lze použít k léčbě dalších pacientů a my jsme odhodláni je k těmto
More news about: Critical Path Institute
Mar 27, 2026, 13:22 ET El Critical Path Institute lanza 'One to Millions' para transformar el futuro de la medicina
escalable para ofrecer medicamentos ASO individualizados a pacientes con enfermedades nanorraras. Hemos descubierto y desarrollado más de 25 ASO que han permitido el tratamiento de más de 45 pacientes con estas enfermedades hasta la fecha. Muchos de estos nuevos medicamentos ASO pueden utilizarse para tratar
More news about: Critical Path Institute
Mar 27, 2026, 13:20 ET Critical Path Institute uruchamia inicjatywę „Od jednego do milionów", aby zmienić przyszłość medycyny spersonalizowanej w skali globalnej
danych, gdzie każde przełomowe odkrycie wspiera kolejne".„W n-Lorem opracowaliśmy solidny i skalowalny proces dostarczania spersonalizowanych leków ASO pacjentom z ultrarzadkimi chorobami. Do tej pory odkryliśmy i opracowaliśmy ponad 25 takich terapii, które umożliwiły leczenie ponad 45 pacjentów. Wiele
More news about: Critical Path Institute
Mar 27, 2026, 13:17 ET Critical Path Institute spúšťa program „One to Millions" - zmena budúcnosti individualizovanej medicíny v globálnom meradle
extrémne zriedkavými ochoreniami poskytovať individualizované lieky ASO. Objavili a vyvinuli sme viac ako 25 ASO, ktoré doteraz umožnili liečbu viac ako 45 pacientov s extrémne zriedkavými ochoreniami. „Mnohé z týchto nových liekov ASO sa dajú využiť na liečbu väčšieho počtu pacientov a my sme odhodlaní
More news about: Critical Path Institute
Mar 27, 2026, 13:15 ET Le Critical Path Institute lance l'initiative « One to Millions » pour redessiner l'avenir de la médecine individualisée à l'échelle mondiale.
évolutif pour apporter des médicaments ASO individualisés à des patients nano-rares. Nous avons découvert et développé plus de 25 oligonucléotides antisens qui ont permis de traiter plus de 45 patients nanorares à ce jour. Beaucoup de ces nouveaux médicaments ASO peuvent être utilisés pour traiter davantage
More news about: Critical Path Institute
Mar 26, 2026, 14:17 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
built a robust and scalable process to bring individualized ASO medicines to nano-rare patients. We have discovered and developed more than 25 ASOs that have enabled treatment of more than 45 nano-rare patients to date. Many of these new ASO medicines can be used to treat more patients and we are committed
More news about: Critical Path Institute
Mar 26, 2026, 14:01 ET Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
built a robust and scalable process to bring individualized ASO medicines to nano-rare patients. We have discovered and developed more than 25 ASOs that have enabled treatment of more than 45 nano-rare patients to date. Many of these new ASO medicines can be used to treat more patients and we are committed
More news about: Critical Path Institute